Phase 1 · New Haven, CT
Phase 1 clinical trials in New Haven, CT
34 recruiting studies have a site in New Haven.
34 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 1/Phase 2
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Regeneron Pharmaceuticals
- Location
- New Haven, CT + 16 other US sites
- Eligibility basics
- Ages 2+ · Men only
- RecruitingPhase 1/Phase 2
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With…
Cabaletta Bio
- Location
- New Haven, CT + 9 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
Azitra Inc.
- Location
- New Haven, CT + 5 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
Hoffmann-La Roche
- Location
- New Haven, CT + 5 other US sites
- Eligibility basics
- Ages 18+ · Men only
- RecruitingPhase 1/Phase 2
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Sumitomo Pharma America, Inc.
- Location
- New Haven, CT + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Jazz Pharmaceuticals
- Location
- New Haven, CT + 20 other US sites
- Eligibility basics
- Ages 12–75
- RecruitingPhase 1/Phase 2
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
Kyowa Kirin Co., Ltd.
- Location
- New Haven, CT + 3 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1/Phase 2
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
Monument Therapeutics Limited
- Location
- New Haven, CT + 14 other US sites
- Eligibility basics
- Ages 17–30
- RecruitingPhase 1/Phase 2
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)
Noveome Biotherapeutics, formerly Stemnion
- Location
- New Haven, CT + 7 other US sites
- Eligibility basics
- Ages 0 mo–2 mo
- RecruitingPhase 1
Study of NTX-2001 on Alcohol Consumption in Alcohol Use Disorder
Newleos Therapeutics, Inc.
- Location
- New Haven, CT
- Eligibility basics
- Ages 21–60
Who these studies look for
Phase 1 studies often have narrow eligibility: specific age and weight ranges, no recent participation in another study, no nicotine, and limits on medications. Some Phase 1 studies recruit patients rather than healthy volunteers, so check each listing.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.